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Abstract
Introduction: Systemic sclerosis (SSc) complicated by pulmonary arterial hypertension (PAH) carries a poor
prognosis, despite pulmonary vascular dilating therapy. Platelet-derived growth factor receptor-b (PDGFR-b) and
epidermal growth factor receptor (EGFR) are potential therapeutic targets for PAH because of their proliferative
effects on vessel remodelling. To explore their role in SScPAH, we compared PDGFR- and EGFR-mmunoreactivity in
lung tissue specimens from SScPAH. We compared staining patterns with idiopathic PAH (IPAH) and pulmonary
veno-occlusive disease (PVOD), as SScPAH vasculopathy differs from IPAH and sometimes displays features of
PVOD. Immunoreactivity patterns of phosphorylated PDGFR-b (pPDGFR-b) and the ligand PDGF-B were evaluated
to provide more insight into the patterns of PDGFR-b activation.
Methods: Lung tissue specimens from five SScPAH, nine IPAH, six PVOD patients and five controls were examined.
Immunoreactivity was scored for presence, distribution and intensity.
Results: All SScPAH and three of nine IPAH cases (P = 0.03) showed PDGFR-b-immunoreactivity in small vessels
(arterioles/venules); of five SScPAH vs. two of nine IPAH cases (P = 0.02) showed venous immunoreactivity. In small
vessels, intensity was stronger in SScPAH vs. IPAH. No differences were found between SScPAH and PVOD. One of
five normal controls demonstrated focally mild immunoreactivity. There were no differences in PDGF-ligand and
pPDGFR-b-immunoreactivity between patient groups; however, pPDGFR-b-immunoreactivity tended to be more
prevalent in SScPAH small vasculature compared to IPAH. Vascular EGFR-immunoreactivity was limited to arterial
and arteriolar walls, without differences between groups. No immunoreactivity was observed in vasculature of
normals.
Conclusions: PDGFR-b-immunoreactivity in SScPAH is more common and intense in small- and post-capillary
vessels than in IPAH and does not differ from PVOD, fitting in with histomorphological distribution of vasculopathy.
PDGFR-b immunoreactivity pattern is not paralleled by pPDGFR-b or PDGF-B patterns. PDGFR-b- and EGFR-
immunoreactivity of pulmonary vessels distinguishes PAH patients from controls.
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Introduction
Systemic sclerosis (SSc) is an autoimmune disease char-
acterized by dysfunction of endothelium, an altered
immune tolerance and the deposition of excessive
amounts of extra-cellular matrix components in multi-
ple organ systems (reviewed by Gabrielli in [1]). Pul-
monary involvement, either lung fibrosis or pulmonary
arterial hypertension (PAH), is the leading cause of
death in SSc [2]. Patients with SSc are at high risk of
developing PAH, with estimated prevalences ranging
from 7.9 to 12% [3,4]. SScPAH carries a poor prognosis
with three-year patient survival rates of 47 to 56%
despite therapy [5-8], although survival has improved
when compared with historical series. Still, these survi-
val rates are worse compared to, for example, idiopathic
PAH (IPAH). In SScPAH, the clinical benefit from cur-
rent PAH therapies also compares unfavourably to that
of IPAH [9-11], although some have been reported
effective [12,13]. SScPAH also differs from IPAH with
respect to pulmonary and hemodynamic function
[14-17]. Notably, SScPAH typically has lower right ven-
tricular- and pulmonary artery pressures as well as diffu-
sion capacity of the lung for carbon monoxide
[6,14,15,17,18]. Pulmonary vasculopathy in SScPAH dif-
fers qualitatively from that of IPAH and resembles pul-
monary veno-occlusive disease (PVOD), a rare form of
PAH, in some instances [19,20]. It seems reasonable to
assume that the clinical and histomorphologic differ-
ences point to quantitative or even qualitative differ-
ences in pathogenetic mechanisms of pulmonary
vascular lesions in SScPAH and IPAH.
Growth factor receptors, such as platelet-derived
growth factor receptor (PDGFR-b) and epidermal
growth factor receptor (EGFR), have been implicated in
the pathogenesis of SSc. SSc skin and cultured fibro-
blasts demonstrate enhanced protein expression of
PDGFR-b, and in SSc patients with progressive disease,
increased PDGFR-b-plasma levels have been found
[21-25]. Imatinib, a dual inhibitor of the tyrosine kinase
c-Abl and PDGFR, has been shown to inhibit progres-
sion and to induce regression of fibrosis in vivo [26]. In
addition, increased expression of EGFR in fibroblasts
from patients with SSc has been shown [27,28]. Indirect
relations with the EGFR signaling system and TGF-b, an
important pro-fibrotic mediator in SSc, have been
described [27]. In pulmonary hypertension, a role of
PDGFR-b and EGFR in the improvement of hemody-
namic function has been suggested in animal models
[29-31]. It is noteworthy in this context that PDGFR-b
plays a role in activation of EGFR [32]. In IPAH
patients, increased and activated PDGFR-b has been
demonstrated in pulmonary arteries [33]. Moreover,
there is anecdotal evidence that inhibition of PDGFR-b
is effective in patients with IPAH and in patients with
PVOD [34-37]. The role of PDGFR-b and EGFR in
SScPAH, however, is as yet unclear.
Here, we examined the presence, localization and
intensity of immunostaining for PDGFR-b and EGFR in
the pulmonary vasculature of SScPAH, and compared
these with IPAH, PVOD, and normal controls. Phos-
phorylated (p) PDGFR-b and PDGF-B immunoractivity
was evaluated to give more insight in activation patterns
of PDGFR-b.
Materials and methods
Patients
The diagnosis of SScPAH, IPAH and PVOD was verified
by reviewing the medical records. Only patients diag-
nosed with PAH upon right heart catheterization, with a
mean resting pulmonary arterial pressure (mPpa) ≥25
mmHg and a pulmonary capillary wedge pressure ≤15
mmHg, were included. The diagnosis of SSc was estab-
lished by a rheumatologist. SSc patients had to fulfil the
preliminary ACR classification criteria for SSc and were
classified according to LeRoy et al. [38,39]. Patients with
restrictive disease as indicated by total lung capacity as
a percentage of predicted (TLC%) <70%, vital capacity
(VC%) <70% and/or severe fibrosis on HRCT scan were
excluded. Lung tissue from five subjects who had died
from extra-pulmonary trauma and who had no cardiore-
spiratory medical history, was used as a control. Histo-
pathological diagnosis of pulmonary vascular disease
was confirmed by independent reading by two patholo-
gists (WJM, KG). PVOD was diagnosed based on the
presence of a picture of patchy intense capillary conges-
tion in the alveolar parenchyma, and obliterative intimal,
loosely textured fibrosis of small veins and venules.
PVOD cases did not have arterialised interlobular veins:
this is indicative of congestive vasculopathy [40,41].
The cases were collected from the Departments of
Pulmonary Diseases and Rheumatology of the VU Uni-
versity Medical Center, Amsterdam and from the
Department of Rheumatology of the Radboud University
Nijmegen Medical Center, Nijmegen, both in The Neth-
erlands. The study, including the use of archived tissue
was approved by the Institutional Review Board on
Research Involving Human Subjects of the VU Univer-
sity Medical Center.
Tissue preparation and immunohistochemistry
Immunohistochemistry was performed on formalin-fixed
paraffin-embedded 4 μm sections of lung tissue. All sec-
tions were stained in one batch for each marker. Anti-
bodies against PDGFR-b (Cell Signaling Technology,
Danvers, MA, USA) and pPDGFR-b (Novus Biologicals,
Littleton, CO, USA) were used at dilutions of 1:50 and
1:150, respectively. Active PDGF is built up by polypep-
tides that form hetero- and homodimers. An antibody
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specific for the PDGF-B form (Novus Biologicals) was
used; it reacts with the PDGF (AB) and PDGF (BB) pro-
tein. The dilution used for this antibody was 1:400. For
EGFR staining, a monoclonal antibody against EGFR
(Novocastra, Newcastle upon Tyne, UK) was used.
Immunostaining for the constitutively expressed
endothelial marker CD31 (PECAM-1, clone JC70a,
Dako, Glostrup, Denmark) served as a reference for the
exact localization of PDGFR-b and EGFR staining, as
well as for PDGFR-b- and EGFR staining intensity, as
staining intensity might be influenced by age of the
blocks and duration of fixation. Isotype-matched con-
trol-staining was performed with rabbit anti-FITC IgG
(Invitrogen, Camarillo, CA, USA). Additional detail on
immunostaining is provided in an online data supple-
ment (Additional file 1; figures of isotype-matched con-
trol staining: Additional file 2).
Scoring
Intensity of immunoreactivity was scored semi-quantita-
tively as absent, mild, moderate and strong on a 0 to 3
point scale. Immunoreactivity was assessed in pulmon-
ary arteries, arterioles, capillaries, venules and veins,
and, where applicable, in intima, media and adventitia.
Arteries were identified by their accompanying bronch-
iole and the presence of a lamina elastica interna and
externa. Vessels were identified as arteriole when their
parent artery could be identified. In case arterioles or
venules could not be distinguished by their anatomical
localisation, they were collectively designated as “small
vessels”. Veins were identified in case they were located
in interlobular septa, and venules in case they could be
anatomically deduced from a draining vein. Intimal
fibrosis was recognizable by Elastica von Gieson-stained
slides.
The overall distribution of immunoreactivity in vessels
was scored as focal, multifocal or widespread, with refer-
ence to the type of vessel and micro-anatomical localiza-
tion. In case of pPDGF-b and PDGF-B, positively
stained cells were assessed as 0 to 25%, 25 to 50%, 50 to
75% and >75%. Staining was designated as focal if 25%,
multifocal if 25 to 75% and widespread if more than
75% of the cells were positively stained. Scoring took
place by two independent readers (KG, MJO) blinded to
the clinical diagnoses. Discrepant scores were reviewed
to reach consensus. In none of the cases was there
disagreement.
Statistics
SPSS 12.0 software package (Chicago, IL, USA) was used
for statistical analyses. The Kruskal-Wallis test was used
for comparison of means concerning demographic-, pul-
monary function- and hemodynamic parameters. For
the comparison of the presence and of the intensity of
immunoreactivity, Fisher’s Exact test was used to com-
pare non-parametric data between groups. A P-value <
0.05 was considered statistically significant. Other para-
meters were analysed descriptively due to lack of statis-
tical power.
Results
Lung tissue samples from five SScPAH, nine IPAH, six
PVOD patients and five controls were collected. Sam-
ples had been obtained at autopsy (n = 17), open lung
biopsy (n = 5; one SScPAH patient, four PVOD
patients) or at lung explantation (n = 3; one SScPAH,
one IPAH and one PVOD patient). Patient characteris-
tics are shown in Table 1. The SSc patients were classi-
fied as having the limited cutaneous form of the disease
[40]. The groups did not differ significantly with respect
to mean age. None of the patients outside the SSc
group had been diagnosed with systemic sclerosis. The
hemodynamic parameters, listed in Table 2, were not
significantly different between the SScPAH, IPAH and
PVOD groups. CD31 staining intensity varied only mar-
ginally among cases.
PDGFR-b immunoreactivity
In SScPAH, PDGFR-b immunoreactivity was present in
the complete spectrum of the pulmonary vasculature, in
vessels both with and without intimal fibrosis. PDGFR-b
was expressed focally in the adventitia and media of
axial arteries and arterioles. In the intimal layer of the
small vessels, all SScPAH patients demonstrated, albeit
focally, immunoreactivity (Figure 1A, B). In the capil-
laries, PDGFR-b immunoreactivity was widespread in
each of the five SScPAH patients (Figure 1A, B, D). This
immunoreactivity was present in areas with and without
congestion. At venular-venous level, in four out of five
SScPAH patients a mild, focal PDGFR-b immunoreac-
tivity was observed in the intima (Figure 1F).
In IPAH, PDGFR-b immunoreactivity of the intimal
and adventitial layers of the arteries and the arterioles
was focally observed (Figure 1G). Only three out of nine
IPAH patients revealed a focal immunoreactivity of the
intima in small vessels. The prevalence was significantly
lower as compared with SScPAH (P = 0.03) (Figure 2).
Moreover, intensity of immunoreactivity in the pooled
arterioles and small vessels was weaker in IPAH than in
SScPAH (P = 0.02) (Figure 3). The interlobular veins
and venules were focally, mildly stained, but, again, in
lower frequency in IPAH than in SScPAH (P = 0.02).
Capillaries were PDGFR-b positive in eight out of nine
IPAH cases. Plexiform lesions, observed in eight out of
nine IPAH cases, showed mild PDGFR-b positivity: in
some cases there was only immunoreactivity of endothe-
lium while in other lesions there was immunoreactivity
of endothelial and subendothelial stromal cells, with
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Table 1 General patient characteristics
SScPAH
N = 5
IPAH
N = 9
PVOD
N = 6
Control
N = 5
Age, yrs 51 (32 to 60) 53 (23 to 59) 33 (23 to 59) 33 (24 to 76)
Male/Female (n) 1/4 2/7 3/3 5/0
Antibody (Ab) profile anti-centromere:
5 (100%)
0 0
Disease duration of PAH at time of death/biopsy (yrs) 1 (0.1 to 4.0) 2.6 (0.8 to 9.0) 1.9 (0.08 to 5.0)
Therapy at time of
death/biopsy
Monotherapy:
prostacycline 3 6 4
PDE-5 inhibitor 0 1 0
ERA 0 1 2
Combination therapy:
Prostacycline+ERA+ 0 0
PDE-5 inibitor (n) 1
ERA+PDE-5 inhibitor (n) 1 0 0
ERA+prostacycline (n) 0 1 0
Limited cutaneous SSc, n (%) 5 (100%)
SSc disease duration, yrs * 2 (1 to 34)
Raynaud phenomenon duration, yrs 13 (1 to 40)
Values expressed as median (range) or otherwise as stated. * Since first non-Raynaud symptom, at time of diagnosis of pulmonary arterial hypertension.
ABS, atrial balloon septostomia; ERA, endothelin receptor antagonist; IPAH, idiopathic PAH; PDE-5, phosphodiesterase 5; PVOD, pulmonary veno-occlusive disease;
SScPAH, systemic sclerosis-associated pulmonary arterial hypertension (PAH).
Table 2 Haemodynamic parameters
SScPAH
N = 5
IPAH
N = 9
PVOD
N = 6
mRpa, mmHg 10 (6 to 18)
(n = 4)
11(7 to 23)
(n = 5)
10 (5 to 15)
(n = 5)
sPpa, mmHg 78 (70 to 101)
(n = 5)
100 (62 to 109)
(n = 9)
76 (58 to 100)
(n = 6)
mPpa, mmHg 55 (43 to 71)
(n = 5)
55 (43 to 76)
(n = 7)
49 (45 to 70)
(n = 6)
PCWP,mmHg 9 (5 to 12)
(n = 5)
7 (1 to 12)
(n = 7)
5 (5 to 11)
(n = 6)
PVR,
dynes·s · cm-5
1054 (627 to 3278) (n = 4) 957 (916 to 1587) (n = 6) 750 (479 to 1483) (n = 7)
CI, l/min·m2 2.2 (1.1 to 2.9)
(n = 7)
2.4 (1.3 to 3.2)
(n = 8)
2.6 (1.9 to 3.1)
(n = 6)
FEV1, % 92 (77 to 97) (n = 4) 80 (56 to 111)
(n = 8)
82 (74 to 95) (n = 6)
TLC, % 87 (81 to 115)
(n = 3)
94 (78 to 113)
(n = 9)
90 (81 to 105)
(n = 6)
VC, % 99 (88 to 120)
(n = 4)
87 (58 to 119)
(n = 8)
*
TLCO, % 35 (26 to 57)
(n = 4)
60 (52 to 90)
(n = 8)
49 (20 to 69)
(n = 6)
Values expressed as median (range) or otherwise as stated. * not available
CI, cardiac index; FEV1 %, percentage predicted of forced expiratory volume; IPAH, idiopathic PAH; mRpa, mean right atrial pressure; PCWP, pulmonary capillary
wedge pressure; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; sPpa, mPpa, systolic, mean pulmonary artery pressures; SScPAH,
systemic sclerosis-associated pulmonary arterial hypertension (PAH); TLC %, percentage of predicted total long capacity; TLCO %, percentage predicted of transfer
factor of the lung for carbon monoxide; VC, percentage predicted of vital capacity.
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Figure 1 Plateled-derived growth factor receptor (PDGFR)-b immunoreactivity in pulmonary vessels in SScPAH, IPAH and PVOD.
(Original magnification 200×). A) PDGFR-b immunoreactivity in the endothelial layer of a small corner vessel without fibrosis in SScPAH. Note
the epithelial immunoreactivity at the alveolar attachments of the corner vessel, serving as an internal positive control. B) PDGFR-b
immunoreactivity in the endothelium of a small corner vessel with fibrosis in SScPAH, and in the (congested) capillary endothelium. C) Absence
of PDGFR-b immunoreactivity in the endothelial layer of a small corner vessel with intimal fibrosis, in an area of capillary congestion, in PVOD.
There is epithelial immunoreactivity at the alveolar attachments of the corner vessel. D) PDGFR-b immunoreactivity in endothelial cells of
capillaries in a SScPAH patient. E) Intense PDGFR-b endothelial immunoreactivity in an area of congestion in a PVOD patient. F) PDGFR-b
endothelial immunoreactivity in a vein in a SScPAH patient. G) PDGFR-b immunoreactivity in the basal side of the endothelium of an arteriole
with intimal fibrosis and media hyperplasia in an IPAH patient. H) PDGFR-b immunoreactivity in a plexiform lesion in an IPAH patient;
immunoreactivity of basal side of the endothelial cells (insert) in the glomeruloid lesion, surrounded by vein-like branches (dilatation lesions).
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thin lines of positive immunoreactivity demarcating the
basal side of endothelial cells (Figure 1H).
Two out of six PVOD cases demonstrated intimal
immunoreactivity in the entire spectrum of the pulmon-
ary vasculature. Pre-capillary intimal and adventitial
immunoreactivity with a mild intensity was observed
focally in three PVOD patients. In five out of six
patients, a focal immunoreactivity of small vasculature
intima was observed (Figure 2). Capillary immunoreac-
tivity, present in areas with and without congestion, was
widespread (Figure 1E), with an intensity from mild to
strong. No differences were found in prevalence,
localisation or intensity of PDGFR-b in the PVOD
group when compared to the SScPAH or the IPAH
group.
In the control group, only one subject demonstrated,
focally, a mild PDGFR-b immunoreactivity in pre-capil-
lary vessels and capillaries, but not in post-capillary ves-
sels. Figures of control slides are added in an online
data supplement (Additional file 3).
pPDGFR-b immunoreactivity
pPDGFR-b was present in the pre-, post- and capillary
pulmonary vasculature in all patient groups. In Figure 4,
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Figure 2 Number of cases with plateled-derived growth factor receptor (PDGFR)-b-immunoreactivity in the intima of pulmonary
vessels in SScPAH, IPAH, PVOD, controls. Small vessels: those arterioles and/or venules that cannot be distinguished based on their
anatomical localisation. * P < 0.05
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representative pictures of pPDGFR-b immunoreactivity
are displayed. Staining was predominantly present in the
nuclei of the cells. In the pre-capillary vessels, immunor-
eactivity was observed in the smooth muscle cells of the
media in all patient groups. Intimal cells were also
positively stained in the diseased groups. This was seen
in vessels with and without intimal fibrosis. With a cut
off of 25% cell staining, a trend was shown (P = 0.09) in
favor of more positive cell immunoreactivity in small
vasculature in SScPAH patients vs. IPAH patients
Arterioles Small vessels
Moderate
Mild
None
SScPAH IPAH PVOD Control SScPAH IPAH PVOD Control
Figure 3 Intensity of plateled-derived growth factor-receptor (PDGFR)-b-immunostaining in the intima of pulmonary vessels in
SScPAH, IPAH, PVOD and controls. A: arterioles. B: small vessels.For the pooled arterioles and small vessels, intensity in SScPAH was stronger
than in IPAH (P = 0.02). Each image represents one case. Small vessels: those arterioles and/or venules that cannot be distinguished as such
based on their anatomical localisation.
Figure 4 Phosphorylated plateled-derived growth factor receptor (pPDGFR)-b immunoreactivity in pulmonary vessels in SScPAH, IPAH
and PVOD. (Original magnification 200×) A) pPDGFR-b immunoreactivity in endothelial cell nuclei in a small vessel with intimal fibrosis in a
patient with SScPAH. B) pPDGFR-b immunoreactivity in cell nuclei in the intima of an arteriole with concentric laminar intimal fibrosis in a
patient with SScPAH (see also 6B). C) pPDGFR-b immunoreactivity in cell nuclei of a small vessel and capillaries in a PVOD patient. D) pPDGFR-b
immunoreactivity in the basal side of the endothelium, the thickened intima and in smooth muscle cells of the hyperplastic media of an
arteriole of an IPAH patient (see also Figures 1G and 6D). E) pPDGFR-b immunoreactivity in stroma and endothelium of a plexiform lesion in an
IPAH patient. Lower right quadrant parent artery. In the center a glomeruloid lesion surrounded by vein-like branches (dilatation lesions).
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(Figure 5). The capillaries demonstrated immunoreactiv-
ity in all patients with no difference between the groups.
Post-capillary staining was found in the intimal layers of
all SScPAH and PVOD patients and in six out of nine
IPAH patients, without quantitative differences. Bronch-
ioles in all patients and controls uniformly demonstrated
pPGFR-b immunoreactivity in the nuclei of the basal
layers of the epithelium and as such served as a positive
internal control (Figure 4F). Controls showed staining in
the whole pulmonary vascular tree; however, this was a
focal staining, with cell counts not exceeding 25%.
PDGF-B immunoreactivity
PDGF-B demonstrated immunoreactivity in the complete
spectrum of the pulmonary vascular tree in all patient
groups. Representative pictures of PDFG-B are displayed in
Figure 6. One IPAH patient failed to demonstrate immu-
noreactivity in the capillaries and one PVOD patient did
not show PDGF-B staining in the post-capillary vessels.
PDGF-B staining was remarkably widespread in the axial
arteries and arterioles, both in media and intima. The small
vessels demonstrated a widely spread distribution of immu-
noreactivity. The capillaries were mostly stained in a multi-
focal to widespread fashion, as were the venules and veins.
Staining was more widespread as compared with PDGFR-b
and pPDGFR-b, in all patient groups. All the plexiform
lesions in the IPAH patients demonstrated immunoreactiv-
ity of pPDGFR-b and PDGF-B in both the endothelial and
stromal cells. As in pPDGFR-b, PDGF-B was also uni-
formly positively stained in the observed bronchioles in all
subjects, and this yielded a positive internal control.
Controls showed pPDGFR-b- and PDGF immunoreac-
tivity in the pulmonary vessels, however, this was a
focal, nonuniform staining.
EGFR immunoreactivity
EGFR was positive in the basal cell layers of the bron-
chial epithelium, alveolar epithelial cells and type II
pneumocytes in all patient and control cases, serving as
an internal control. Interestingly, focal areas of positively
immunoreactivity type II pneumocytes were found to
surround the pre-capillary vessels (Figure 7A, B) in the
patient cases and in one control case. No differences in
the prevalence of this phenomenon between the patient
groups were observed. Capillaries surrounded by EGFR-
expressing pneumocytes were observed in all SScPAH
patients, in five out of nine IPAH patients and in two
out of six PVOD patients.
EGFR immunoreactivity was focal and weak in the
pulmonary hypertension groups (Figure 7A-C) and was
observed mostly in media and intima of the pulmonary
vessels. No differences in immunoreactivity prevalence
(Figure 8), intensity or distribution between the pulmon-
ary hypertension groups were observed. Most plexiform
lesions demonstrated a weak immunoreactivity of EGFR,
which appeared to be located in subendothelial stromal
cells (Figure 7D). No immunoreactivity of pulmonary
vessels was observed in the control cases.
Discussion
This study demonstrates the presence of PDGFR-b
immunoreactivity in the entire pulmonary vascular bed
of SScPAH patients, with a different staining pattern as
compared to IPAH. There were no differences in
PDGFR-b immunoreactivity between SScPAH and
PVOD. PDGFR-b immunoreactivity was more prevalent
and intense in the PAH groups than in controls. There
was a trend towards more pPDGFR-b-positively stained
cells in SScPAH small vasculature as compared with
75-100%
50-75%
0 2 %
25-50%
SScPAH IPAH PVOD Control
- 5
Figure 5 Amount of phosphorylated plateled-derived growth factor receptor (pPDGFR)-b-positively immunostained cells in intima of
the small vessels in SScPAH, IPAH, PVOD and controls. With a cut off of 25% cell staining, a trend was shown (P = 0.09) in favor of more
positive cell immunoreactivity in small vasculature in SScPAH patients vs. IPAH patients. Each image represents one case.
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IPAH. EGFR was minimally present in the pulmonary
vasculature of SScPAH, IPAH and PVOD, without dif-
ferences between the groups. No EGFR immunoreactiv-
ity was observed in the pulmonary vasculature of
controls.
This is the first study to explore PDGFR-b- and EGFR
immunoreactivity in lung vasculature in SScPAH.
PDGFR-b is implicated in SSc disease [21-26]. In IPAH,
Perros et al. demonstrated PDGFR-b, pPDGFR-b and
PDGF-A and -B expression and activity in remodelled
small pulmonary arteries and plexiform lesions [33]. In
pulmonary capillary haemangiomatosis, an entity that
shows overlap with both PVOD [42] and SScPAH [19],
up-regulation of PDGF-B and PDGFR-ß genes has been
shown in distended capillaries [43]. The present study
supports these findings and extends them by showing
the presence of PDGFR-ß immunoreactivity in SScPAH.
The different immunoreactivity pattern in the pulmon-
ary vasculature compared to IPAH fits in with the dis-
tinctive distribution of vascular lesions in SScPAH. This
might implicate a role for PDGFR-b in small vessel inti-
mal remodeling in SScPAH.
EGFR expression in human pulmonary vasculature
affected by SSc or SScPAH has not been previously
reported. We demonstrate EGFR expression, albeit mild
and focal, in human pulmonary vasculature of SScPAH,
IPAH and PVOD. Dahal et al. [31] failed to show a dif-
ference in EGFR expression in lungs of patients with
end-stage IPAH and normal controls. This apparent dis-
crepancy compared to the present study may be
explained by patient selection, by the use of tissue
obtained at lung transplantation and by the evaluation
of whole lung tissue by Dahal et al.
The inherent drawback of using archival tissue from
different laboratories is shared by other studies. Differ-
ences in preparation and in storage time may have an
unknown influence on the quantity or quality of immu-
noreactivity. However, care was taken to limit the influ-
ence of age of paraffin blocks, and preparation
procedures such as fixation time on epitope availability,
by using the constitutive expression of CD31 as a posi-
tive control within each case. Moreover, the uniform
positive immunoreactivity of bronchiolar epithelium in
pPDGFR-b, PDGF-B and EGFR samples served as an
internal positive control.
Antibodies directed at different epitopes than the ones
we used for our experiments, might generate different
results. This, in combination with differences in antigen
blocking steps, might explain why we did not detect
PDGFR-b immunoreactivity in the media of pulmonary
Figure 6 Plateled-derived growth factor (PDGF) B immunoreactivity in pulmonary vessels in SScPAH, IPAH and PVOD. (Original
magnification 200×). A) PDGF-B immunoreactivity in small vessel and capillaries in a patient with SScPAH. B) PDGF-B immunoreactivity in the
intima layers of an arteriole with concentric laminar intimal fibrosis in a patient with SScPAH (see also 4B). C) PDGF-B immunoreactivity in a small
vessel and (congested) capillaries in a PVOD patient. D) PDGF-B immunoreactivity in the basal side of the endothelium, the thickened intima and
in smooth muscle cells in the hyperplastic media of an arteriole in a IPAH patient. E) PDGF-B immunoreactivity in stroma and endothelium of a
plexiform lesion in an IPAH patient. In the center a glomeroid lesiom surrounded by vein-like branches (dilatation lesions).
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arteries in the IPAH group, in contrast to Perros et al.
[33] However, we did demonstrate PDGFR-b, pPDGFR-
b and PDGF-B immunoreactivity in smooth muscle cells
and endothelial cells of constrictive pulmonary arteries
and plexiform lesions, which is in concordance with
Perros et al. [33] As immunohistochemical immunor-
eactivity demonstrates the presence but not the activity
of (p)PDGFR-b, PDGF-B and EGFR, further studies are
needed to further support the rationale for the use of
receptor antagonists in SScPAH. The small sample size
limits the interpretation of the results. However, only
thoroughly characterized unequivocal cases of SScPAH,
IPAH and PVOD were included, so as to reduce over-
lap. As histopathological information on well-character-
ized SScPAH patients is scarce, the results obtained
here provide valuable exploratory information. However,
they underscore the need for sampling of suitable tissue
specimens in these patient groups for future research,
also into receptor functionality studies. The majority of
the PVOD samples were biopsies, while the samples
from the SScPAH and IPAH group were derived from
autopsy material. We cannot exclude some influence on
results, as there is no knowledge on post-mortem beha-
viour of the (p)PDGFR-b and PDFG-B. Another influen-
cing factor might be the fact that the biopsy group does
not necessarily represent end-stage disease, in contrast
to the explanation- and autopsy samples.
How do we interpret these results? The pattern of
immunoreactivity of PDGFR-b and probably pPDGFR-b
in SScPAH, IPAH and PVOD follows the distinct
Figure 7 Epidermal growth factor receptor (EGFR) immunoreactivity in pulmonary vessels in SScPAH, IPAH and PVOD. (Original
magnification 200×). A) EGFR expression of alveolar epithelium surrounding a parenchymal arteriole (corner vessel) in a SScPAH patient, showing
weak immunoreactivity of the media and endothelium. B) Weak EGFR immunoreactivity of endothelial cells in a SScPAH patient. C) EGFR
expression in media and fibrotic intimal layer of an axial artery of a SScPAH patient. Left lower quadrant: parent artery. Center: glomeruloid
lesion, surrounded by dilatation lesions (original magnification 100×). D) Plexiform lesion in an IPAH patient showing weak stromal EFGR
expression.
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patterns of histomorphologic vasculopathy between
these disease groups [20]. The specific role of PDGFR in
SScPAH vascular remodeling is further supported by
either PDGF or PDGFR autoantibodies [44]. Such anti-
bodies may induce signaling pathways, which eventually
may lead to local intimal fibrosis. No differences in the
small vessel- and post-capillary vasculature were seen
between SScPAH and PVOD. As PVOD-like changes
may be seen in SScPAH pulmonary vasculature [19,20]
it can be speculated that SScPAH and PVOD share acti-
vation of PDGFR-b as a pathophysiologic determinant.
The observation of PDGFR-b immunoreactivity, in
both affected and non-affected vessels, might be inter-
preted as pointing towards longstanding pathogenetic
involvement. pPDGFR-b and PDGF-B showed immu-
noreactivity in the pulmonary vasculature of the dis-
eased patient group, with an increased prevalence as
compared to controls. This supports the pathogenetic
role of the PDGFR-b pathway in PAH. However, this
study neither demonstrated clear parallels in staining
patterns between PDGFR-b and pPDGFR-b nor PDGF-
B in the SScPAH group. This might be explained by
transactivation of PDGFR-b, resulting in phosphoryla-
tion of the PDGFR-b [45]. The extent of involvement of
the PDGFR-b- pPDGFR-b-signalling pathway in PAH
pathogenesis and whether the role of this pathway is dif-
ferent in SScPAH as in IPAH, will need to be investi-
gated in functional studies.
PDGFR-b can be inhibited by imatinib, a TKR inhibi-
tor that also has specificity for the Abl-related gene pro-
tein in the tyrosine fusion protein Bcr-Abl and c-kit.
The effect of imatinib in SSc pathogenesis might be
enhanced by its inhibitory effect on c-Abl, which is
important for the induction of extracellular matrix com-
ponents via TGF-b signaling [46,47]. TGF-b is among
the most important pro-fibrotic SSc-mediators [67].
This, together with the findings in the present study
support the rationale for PDGFR-b targeted therapy in
SScPAH. The effects of such therapy might extend to
EGFR via transactivation by PDGFR-b, leading to altered
signalling of the EGFR [48].
PDGFR-b, its ligand and its phosphorylated state
and EGFR were observed in plexiform lesions of IPAH
patients. Their active participation in plexiform lesion
formation remains speculative, but Perros et al. [33]
demonstrated immunoreactivity of PDGFR-b, PDGF-
BB and phosphorylated PDGFR-b in endothelium-
lined channels, fitting in with the findings in the pre-
sent study. This is the first report of EGFR expression
in plexiform lesions. It can be speculated that EGFR
features in their formation: Tuder et al. demonstrated
that endothelial cells in plexiform lesions expressed
the transcription factor units HIF-1a and HIF-1b [49].
In cancers, HIF-1 participates in the activation of
autocrine signaling pathways involving TGF-a/EGFR
and EGF-2/IGF-1R, which promote cell survival and
proliferation [50,51]. As the role of plexiform lesions
in haemodynamic alterations occurring in PH is
unknown, it is uncertain as to whether treatment
aimed at their growth factor receptors will be effective
in IPAH.
Conclusions
We demonstrated that the PDGFR-b immunoreactivity
pattern in SScPAH differs from that in IPAH, whereas
no differences were observed between SScPAH and
PVOD. This is in line with differences in distribution
and morphologic characteristics of vasculopathy
between the disease groups. This might implicate that
PDGFR-b activation plays a role in pulmonary
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Figure 8 Number of cases with positive immunostaining for epidermal growth factor receptor (EGFR) in the intima of pulmonary
vessels. A: arterioles, B: Small vessels, C: veins) in SScPAH, IPAH, PVOD and normal controls. No staining was observed in the capillaries. Small
vessels: those arterioles and/or venules that cannot be distinguished as such by their anatomical localisation
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hypertension, which is supported by the presence of its
phosphorylated state and the PDGFR-B ligand. The mild
immunoreactivity of EGFR in PAH vasculature as com-
pared to its total absence in controls might be an indi-
cation of its pathogeneity in PAH, too. This study
supports the notion that PDGFR-inhibiting therapy may
be effective in the treatment of PAH and of SScPAH in
particular, and that multikinase inhibitors deserve con-
sideration as an option in future treatment strategies in
pulmonary arterial hypertension.
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